← Eichor
Condition: Squamous Cell Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Squamous Cell Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
Phase N/A · 1 location(s) · City of Hope Medical Center · NCT07224750Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT07177794A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 N
Phase 2/Phase 3 · 10 location(s) · Eikon Therapeutics · NCT07365319A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemoth
NA · 1 location(s) · The Second Affiliated Hospital of Hainan Medical University · NCT07546383A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and N
Phase 3 · 277 location(s) · GlaxoSmithKline · NCT06256588A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Phase 1 · 62 location(s) · Seagen, a wholly owned subsidiary of Pfizer · NCT05208762Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Sara Medek · NCT07497607Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
Phase 2 · 2 location(s) · The Netherlands Cancer Institute · NCT06353906Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cuta
Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT04975152Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
Phase 2 · 6 location(s) · University of Arkansas · NCT05952934Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
Phase 1/Phase 2 · 1 location(s) · Bruce Robinson, MD · NCT07010692Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurg
Phase 1 · 1 location(s) · Shanghai Zhongshan Hospital · NCT07317609A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Phase 1/Phase 2 · 67 location(s) · AstraZeneca · NCT05123482Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 4 location(s) · One-carbon Therapeutics AB · NCT07151040Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Phase 1/Phase 2 · 60 location(s) · AstraZeneca · NCT05797168The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carc
Phase 2 · 1 location(s) · Hospital of Stomatology, Wuhan University · NCT06277791Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell
Phase 2 · 1 location(s) · Groupe Oncologie Radiotherapie Tete et Cou · NCT06640725Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma
NA · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT07627347Chemoradiotherapy in Unresectable Esophageal Cancer
Phase 1/Phase 2 · 5 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT04278287A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell C
Phase 3 · 306 location(s) · AstraZeneca · NCT06129864DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07162506Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma
Phase 2 · 1 location(s) · NYU Langone Health · NCT03215719Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance C
Phase 3 · 301 location(s) · National Cancer Institute (NCI) · NCT07061977Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
Phase 2 · 1 location(s) · Akeso · NCT07263919A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophag
Phase 3 · 1 location(s) · Renmin Hospital of Wuhan University · NCT05919030Thermotherapy in Addition to SOC Palliative Radiotherapy
NA · 2 location(s) · King's College London · NCT06659146Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy
NA · 1 location(s) · Anhui Provincial Hospital · NCT06602843Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06137274A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Ce
Phase 2 · 1 location(s) · University of Illinois at Chicago · NCT05613413
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.